Kornimate/medical-research-clean huggingface dataset:
oral prednisolone in the treatment of esophageal stricture after esophageal surgery

Conditions: Esophageal Anastomotic Stricture

Summary: this study is safety and proof-of-concept study for oral prednisolone in the treatment of esophageal stricture after esophageal surgery. the patients who develop the severe esophageal strictures from 28 days after esophageal surgery are included. primary outcomes are safety and success rate of this treatment.

esophageal strictures are common complications after surgery and aggressive endoscopic submucosal dissection (esd) for early-stage esophageal cancer and adenocarcinoma. however, patients, who develop esophageal strictures after extensive operations, usually develop refractory strictures. although there are several treatments for refractory strictures, their utility is limited. yamaguchi and colleagues have developed new treatments using oral prednisolone. they have shown the safety and potential efficacy to prevent esophageal strictures after esd. however, the efficacy and safety of oral prednisolone is not evaluated to esophageal stricture after esophageal surgery. this study is safety and proof-of-concept study for oral prednisolone in the treatment of esophageal stricture after esophageal surgery. the patients who develop the severe esophageal strictures from 28 days after esophageal surgery are included. primary outcomes are safety and success rate of this treatment.

Eligibility criteria:
inclusion criteria: * the patients who develop the severe esophageal strictures from 28 days after esophageal surgery exclusion criteria: * pulmonary and cardiac disorders * liver and renal dysfunctions * allergic * pregnancy * infectious disease * unsuitable condition
serum lipase and severity of pancreatic injury.

Conditions: Pancreatic Injury

Summary: diagnosis of pancreas injury is not easy at first consult. it's a retrospective study, in children under 15 years and 3months, between january 1st 2010 to august 31th 2019, to prove that the first level of lipase is correlated with the severity of pancreatic injury. every children with elevated serum lipase after trauma during those years will be selected. the children with pancreatic tumors will be excluded. american association of surgeon trauma (aast) classification of pancreas injury will be used to grade severity. children will be divided in two groups : one including pancreatic lesion with duct injury and one without duct injury. data will include mechanism of injury, associated injury, length of stay, maximal lipase level, nutritional care and local complications will be noted.

the main objective of this study is to determine if there is a correlation between the initial serum lipase and the severity of the pancreatic injury.

Eligibility criteria:
inclusion criteria: * children under 15 years 3 months with elevated lipase serum level after trauma. exclusion criteria: * elevation of lipase secondary to pancreatic tumor

Keywords: lipase pancreatic trauma pseudocysts
chidamide and pd-1 inhibitor plus anlotinib for her2-low breast cancer that has spread or cannot be surgically removed

Conditions: Breast Cancer

Summary: this phase ii study was designed to assess the efficacy and safety of the combination of pd-1 inhibitor, tucidinostat (chidamide), a histone deacetylase inhibitor, and anlotinib in advanced breast cancer. participants must have her2-low and pd-l1 positive （cps≥1）breast cancer that has been treated before. participants' cancer: cannot be removed by an operation has spread to other parts of the body


Eligibility criteria:
inclusion criteria: 1. has pathologically documented breast cancer that: * is unresectable or metastatic * has low-her2 expression defined as ihc 2+/ish- or ihc 1+ (ish- or untested) * is hr-positive * has progressed on, and would no longer benefit from, endocrine therapy * has been treated with 0 to 1 prior lines of chemotherapy in the recurrent or metastatic setting * was never previously her2-positive (ich 3+ or ish+) on prior pathology testing (per american society of clinical oncology-college of american pathologists \[asco-cap\] guidelines) * pd-l1 positive （cps≥1） 2. has documented radiologic progression (during or after most recent treatment) 3. has adequate archival tumor samples available or is wiling to provide fresh biopsies prior to randomization for: * assessment of her2 status * assessment of post-treatment status 4. has at least 1 measurable lesion per response evaluation criteria in solid tumors 1.1 5. has protocol-defined adequate cardiac, bone marrow, renal, hepatic and blood clotting functions 6. male and female participants of reproductive/childbearing potential, agrees to follow instructions for method(s) of contraception and agrees to avoid preserving ova or sperm for at least 4.5 months after treatment (or longer, per locally approved labels) exclusion criteria: 1. allergies to any monoclonal antibody or tucidinostat preparation have been known, and hypersensitivity reactions of more than 3 levels have occurred 2. previously received histone deacetylase inhibitors,or immune checkpoint inhibitor, or angiogenesis inhibitors. 3. subjects with any active, known or suspected autoimmune disease or history of autoimmune disease. 4. known active cns metastases and/or carcinomatous meningitis. 5. received a live vaccine within 4 weeks of the first dose of study medication. 6. major surgery received or severe traumatic injury, fracture, or ulcer occurred within 4 weeks of the first dose of study medication. 7. pregnant or lactating female. 8. uncontrolled clinically significant systemic diseases, including active infection, unstable angina, angina occurred within 3 months,≥ nyha ii congestive heart failure, myocardial infarction occurred within 6 months, severe arrhythmia, liver, kidney, or metabolic disease. 9. participate in other clinical trials currently or within 4 weeks prior to enrollment.
a study of the sense of smell in relatives of parkinson's disease patients

Conditions: Parkinson Disease; Parkinsonian Syndrome

Summary: in this study, individuals complete and return a mail survey, specifically a 40 item scratch and sniff smell test.

this study would extend the findings of previous studies by characterizing the performance of the 40-item upsit in a cohort of first-degree relatives of parkinson's disease (pd) patients. the results would also validate the use of the university of pennsylvania smell identification test (upsit) as a mail-survey instrument. once identified, these individuals could be followed as a potentially at-risk cohort to determine if the screening evaluation was predictive of later developing parkinson's disease. the results from this pilot study have the potential to guide the use of olfactory testing using the upsit as a screening tool, and to provide necessary preliminary data for planning clinical trials to prevent the occurrence of pd in at-risk individuals.

Eligibility criteria:
inclusion criteria: * subject must be a first-degree relative of a pd patient with diagnosis confirmed by a movement disorders specialist at the institute for neurodegenerative disorders * subject must not carry a diagnosis of pd or other neurodegenerative disorder * subject must be either at least 50 years old or within 10 years of the age of onset of their affected relative * subject must be a non-smoker * subject must have no other known reason for abnormal olfaction (e.g. nasal trauma)

Keywords: parkinsonian syndrome
pretreatment with dienogest in women with endometriosis undergoing in vitro-fertilization after a previous failed cycle

Conditions: Endometriosis; Endometriosis Ovary; IVF

Summary: it is generally assumed that the major causes of in vitro fertilization (ivf) failure in women with endometriosis are diminished ovarian reserve, impaired endometrial receptivity and low quality of embryos. the use of prolonged courses of hormone therapy may play an important role in the strategy of overcoming endometriosis-related infertility. the aim of this study was to evaluate the use of dienogest (dng) before an ivf cycle in women with endometriosis undergone a previous ivf failed cycle

the primary outcomes of the study are clinical pregnancy rate and live birth rate after reaching 24 week's gestation. secondary outcomes of the study are: changes in the diameter and volume of the largest endometrioma, total gonadotropin dose administered, number of mature oocytes collected, number of two-pronuclear (2pn) embryos, number of blastocysts.

Eligibility criteria:
inclusion criteria: * diagnosis of endometriosis at magnetic resonance imaging or transvaginal ultrasonography; * one failed previous ivf cycle (including failure of frozen embryo transfer); * basal fsh \< 14.0 iu/l; * antimullerian hormone (amh) blood level \>= 0.5 g/ml; * normal thyroid-stimulating hormone and prolactin. exclusion criteria: * history of surgery for endometriosis; * history of uterine or adnexal surgery; * use of hormonal therapies for the treatment of endometriosis related pain within 6 months before ivf; * adenomyosis (magnetic resonance imaging or transvaginal ultrasonography); * hydrosalpinx; * submucosal fibroids; * body mass index (bmi) ≥ 30 kg/m2; * severe male factor infertility (\< 5 million total motile sperm count).

Keywords: endometriosis ivf
robotic versus laparoscopic low anterior resection for rectal cancer

Conditions: Rectal Neoplasms; Sexual Dysfunction; Urinary Incontinence; Quality of Life

Summary: prospective randomized trial comparing robotic versus laparoscopic low anterior resection for rectal cancer. primary endpoint: compare urinary dysfunction between robotic and laparoscopic approach.

prospective randomized trial comparing robotic versus laparoscopic low anterior resection for rectal cancer. the aim of the study is to compare two surgical approaches (robotic versus laparoscopic) for rectal cancer treatment regarding functional outcomes (sexual and urinary dysfunctions), quality of life, post operative outcomes and oncologic outcomes. patients with the diagnosis of t3 mid and low rectal cancer will be randomized to robotic or laparoscopic procedure after neoadjuvant chemoradiation. quality of life questionnaires and urodynamic test will be applied before and after the surgical procedures.

Eligibility criteria:
inclusion criteria: * mid or low rectal adenocarcinoma * performance status (ecog) 0 - 2 exclusion criteria: * metastatic disease * congestive heart failure * renal failure * diabetes * pregnancy * neurologic disorders * alfa blockers user * patients who are candidates to apr ( abdomino-perineal resection)

Keywords: rectal neoplasms sexual dysfunctions urinary incontinence quality of life robotic surgical procedures laparoscopy
the characteristics and risk factors of breast cancer patients trend distinctive regional differences: a cross-sectional study

Conditions: Breast Cancer; Breast Neoplasms; Breast Cancer Invasive; Breast Cancer Stage; Breast Cancer Metastatic

Summary: this cross-sectional study, conducted at the sindh institute of urology and transplantation (siut), involved a retrospective data review of all the patients diagnosed with breast cancer from march 2017 to december 2021. the demographic characteristics, clinical presentation, stage of the disease, and histopathological characteristics were analyzed.


Eligibility criteria:
inclusion criteria: * all patients diagnosed with breast cancer exclusion criteria: * the patients that were lost to follow-up after the first consultation and those consulting for a second opinion were excluded from the study.

Keywords: breast cancer clinical audit breast cancer risk factors breast cancer screening clinicopathological characterisitics
evaluating the effects of psychological stress on salivary biomarkers in pediatric patients visiting pediatric and general dental clinic

Conditions: Salivary Cortisol; Salivary Alpha Amylase

Summary: the goal of this study is to test the effect of psychological stress on pediatric patients visiting specialized and general dental clinic by measure salivary cortisol and salivary alpha amylase and by use children fear survey schedule -dental subscale . 80 male subjects will be enrolled in this study between 4-6 years old with first dental visit ,40 subjects visiting specialized pediatric dental clinic to see the effect of specific environment and attitude of dentist on child stress ,and 40 subjects visiting general dental clinic with normal environment and general dentist . the method of study is by taking two saliva sample from child , first when he will enter the clinic at reception and second after half hour when he will diagnosed without any type of treatment.


Eligibility criteria:
inclusion criteria: * male * 4-6 years old * first dental visit * patients with no systemic disease exclusion criteria: * medically compressed patient * patients with systemic disease
repeated hbo therapy in myeloma patients undergoing high-dose therapy and auto-hct

Conditions: Myeloma

Summary: subjects with multiple myeloma (mm) who are considered eligible for high-dose therapy and autologous stem cell transplantation by the transplant team at wci will be enrolled in the study.

subjects with multiple myeloma (mm) who are considered eligible for high-dose therapy and autologous stem cell transplantation by the transplant team at wci will be enrolled in the study. subjects will receive hbo therapy on days 0, +1 and +2 of the transplant. the treatment consists of exposure to hyperbaric oxygen at 2.5 atmospheric absolutes for a total of 90 minutes after compression to 2.5 atmosphere absolutes in a monoplace hyperbaric chamber (model 3200/3200r, sechrist industries, inc., usa), breathing 100% oxygen. subjects will be in the chamber for a total of 120 minutes as approximately 10-15 minutes will be spent during the compression and decompression phases and subjects will have 5-10 minute room air breaks every 30 minutes of hyperbaric oxygen treatment. subjects will be seen daily until neutrophil recovery is documented . after neutrophil recovery is documented, the subjects will be seen in clinic at least weekly through day +100. a final visit will be scheduled day +100. as part of routine care, subjects will be followed daily or as directed by the treating physician until neutrophil recovery, defined as three consecutive days of achieving a neutrophil count of \>500/mm3. laboratory testing will occur per institutional guidelines. follow-up will continue until day +100. donor chimerism and disease status will be determined by bone marrow biopsy on day +30 and day +100 post-transplant.

Eligibility criteria:
inclusion criteria: * subjects with multiple myeloma * subjects must be 18 years old * karnosfsky performance of greater than 70 percent * adequate hepatic, cardiac and pulmonary function * subjects should have new york heart association functional classification of: class 1 or class ii. exclusion criteria: * pregnant or breastfeeding * severe chronic obstructive pulmonary disease requiring oxygen supplementation * history of spontaneous pneumothorax * active ear/sinus infection * sinus surgery within the last 5 years * claustrophobia * history of recurrent seizures within 5 years of study enrollment * evidence of pneumothorax or significant pulmonary fibrosis on chest imaging within 60 days of transplant * prior chest surgery involving thoracotomy or prior direct irradiation to the lungs * subjects who have had intrathecal chemotherapy within 2 weeks of starting preparative regimen or cranial irradiation within 4 weeks of starting preparative regimen * active and uncontrolled viral, fungal or bacterial infection * use of tobacco 72 hours prior to transplant
a study of ursolic acid for primary sclerosing cholangitis

Conditions: Primary Sclerosing Cholangitis

Summary: this is an open-label, active treatment trial to determine the pharmacokinetics of orally administered ursolic acid and to assess the potential efficacy and safety of ursolic acid in subjects with primary sclerosing cholangitis (psc).

in the first phase of this trial, 6 healthy subjects and 2 psc subjects will assigned to ursolic acid taken orally as a single dose of 40 mg, 80 mg, and 120 mg to determine the optimal dose in humans. the second phase of this trial will involve 20 psc subjects assigned to treatment with daily oral ursolic acid at the dose determined to be optimal in the first phase of the study. the treatment will last for 24 weeks with an off-treatment follow up of 28 weeks.

Eligibility criteria:
inclusion criteria: * male or female age 18 - 70 years of age * psc documented by typically cholangiogram findings of strictures and dilations with no evidence of a secondary cause of sclerosing cholangitis * serum alkaline phosphatase greater than 1.5 times the upper limit of the normal reference range at the uc davis health systems clinical laboratory * ast and alt ≤ 10 x uln * serum creatinine \< 2.0 mg/dl * mayo activity index of \< 2 (in those with ulcerative colitis or crohn's colitis) * negative serum pregnancy test for female subjects of childbearing potential, agreement to use a highly effective method of contraception during heterosexual intercourse (females of childbearing potential), lactating females must agree to discontinue nursing before starting study treatment, and barrier contraception during heterosexual intercourse (males not vasectomized). exclusion criteria: * pregnancy * hepatic decompensation defined as ascites (or use of diuretics), episodes of hepatic encephalopathy, variceal bleeding or an inr \> 1.2 * positive hcv rna or hbsag, positive anti-mitochondrial antibody, alcohol consumption greater than 21oz/week for males or 14oz/week for females * clinically significant cardiac disease, history of cholangiocarcinoma, history of liver transplantation, history of cancers, other than non-melanomatous skin cancer, within 5 years prior to screening * ascending cholangitis within 60 days of screening * use of immunosuppressants including 6-mercaptopurine, azathioprine, methotrexate, mycophenolate mofetil, tacrolimus, cyclosporine, and anti-tnf or other biologics within 6 months of enrollment * use of antibiotics including vancomycin, metronidazole, or rifaximin within 60 days of enrollment
longitudinal changes in exercise capacity in children and young adults with sickle cell anemia

Conditions: Sickle Cell Anemia

Summary: the purpose of this study is to use comprehensive exercise testing to examine longitudinal changes in exercise capacity over a 2 year period in children and young adults with sickle cell anemia.

although the burden of sickle cell anemia (sca) on affected individuals is significant, few studies have examined the influence of having sca on such measures of physical function as exercise capacity. moreover, the physiologic basis of poor physical functioning in children with sca is unknown and has not been studied extensively. the purpose of this proposal is to use cardiopulmonary exercise testing (cpet) to gain a comprehensive understanding of longitudinal changes in exercise capacity, and the effect of poor exercise capacity on quality of life in children and young adults with sca. the specific aims of this project are to: 1) measure peak oxygen consumption (vo2), the reference standard for exercise capacity, in children and young adults with sca classified by primary pathophysiologic contributor to their decreased exercise capacity, and 2) compare results of this exercise test with the results of previously completed exercise tests to determine longitudinal changes in exercise capacity. these aims will be performed in 60 subjects with sca and 30 matched controls who participated in a previous study, irb# 2009-13659; "the physiologic assessment of exercise capacity in pediatric sickle cell anemia". in a secondary analysis, we will also study the participants quality of life using a set of validated questionnaires. this study is essential because it will address several areas of exercise capacity, including the longterm effects of physiologic contributors to exercise limitation, that remain fundamental knowledge gaps in sca.

Eligibility criteria:
inclusion criteria: 1. age 8 to 21 years old; and 2. hb ss or s-β0 thalassemia disease, confirmed by hemoglobin analysis; and 3. previously participated in clinicaltrials.gov id: nct01527799 exclusion criteria: 1. inability to perform maximal testing due to physical limitation (e.g. stroke or avascular necrosis); or 2. history of exercise-induced syncope or arrhythmias. subjects will wait at least 2 weeks following any vaso-occlusive pain episode and 12 weeks following any disease-related complication requiring transfusion support. individuals on hydroxyurea will be eligible. a total of 30 controls without sca or sickle cell trait will be matched for age, sex and race and recruited from the siblings, friends or relatives of subjects enrolled on this study

Keywords: sickle cell anemia exercise testing cardiopulmonary disease
doppler flow measurements in patients with misoprostol treatment for arrested pregnancy

Conditions: Missed Abortion

Summary: testing the whether doppler studies after cytotec treatment can predict success of treatment.

all women who are treated with cytotec for a missed abortion at 1st trimester will have a follow up ultrasound exam. doppler measurements will be performed but will be hidden from the clinicians. after the conclusion of treatment, data on doppler would be vevealed in order to see if positive doppler after cytotec is predictive of failure of treatment or the need in several doses of cytotec.

Eligibility criteria:
inclusion criteria: * women with miss abortion who choose treatment with cytotec exclusion criteria:

Keywords: missed abortion, early pregnancy loss.
efficacy of iarulil® in the treatment of recurrent cystitis refractory to escherichia coli extract

Conditions: Recurrent Cystitis

Summary: the purpose of this study is to evaluate the efficacy of combined intravesical therapy with hyaluronic acid and chondroitin sulphate in the treatment of recurrent cystitis refractory to escherichia coli extract

the purpose of this study is to evaluate the efficacy of combined intravesical therapy with hyaluronic acid and chondroitin sulphate(iarulil®) in the treatment of recurrent cystitis refractory to oral escherichia coli extract(uro-vaxom®) and the change of urinary tract infection symptoms after intravesical instillation treatment with iarulil®.

Eligibility criteria:
inclusion criteria: 1. female patients aged between 20 and 80 years 2. patients diagnosed with recurrent cystitis and treated with escherichia coli extract 3. patients with refractory to escherichia coli extract treatment exclusion criteria: 1. child-bearing potential, pregnant or nursing women. 2. residual urine volume \>100ml 3. genitourinary tuberculosis or cancer / anatomical abnomality of genitourinary tract / neurologic abnormality of low urinary tract. 4. history of treatment for acute cystitis within 2weeks.

Keywords: recurrent cystitis hyaluronic acid chondroitin sulphate